Fatty Liver Amelioration Through Bariatric Surgery by Philip Schauer, MD - November 2006 Nonalcoholic fatty liver disease (NAFLD) is found in the vast majority of obese adults and more than half of obese children. Early treatment of the condition is necessary to prevent progression to nonalcoholic hepatosteatitis, fibrosis, cirrhosis and end-stage liver failure or hepatocellular carcinoma. Fortunately, significant weight loss achieved through bariatric surgery can be an effective therapy for NAFLD. ![]() Patients with metabolic syndrome have high levels of oxidative stress, which is known to initiate the inflammatory cascade and cause hepatocellular injury. NAFLD is present in 60 percent of females and 30 percent of males with metabolic syndrome. The beneficial effects of weight loss on NAFLD appear to occur through improved insulin sensitivity. A sustained decrease in circulating glucose and insulin levels followed by the reduction in adipose mass and leptin levels likely reduce fatty infiltration and inflammation, thereby restoring insulin sensitivity. The result is the elimination of the fibrogenic tendencies of leptin, leading to reversal of fibrosis and cirrhosis. While nonsurgical weight loss with diet, exercise and behavior modification has traditionally been considered first-line treatment for NAFLD, significant weight loss with these methods is difficult to achieve and modest weight loss, when accomplished,is often difficult to maintain. Studies of weight loss achieved with pharmacotherapy disagree on its impact on NAFLD. Several studies have shown the positive benefit of surgical weight loss on NAFLD. In one single-center study, 70 patients diagnosed with NAFLD were evaluated extensively and screened for diabetes and the six conditions associated with metabolic syndrome before undergoing laparoscopic bariatric surgery. Intraoperative biopsies were taken, and repeat biopsies were performed postoperatively at a mean of 15 months. These were graded for steatosis, inflammation and fibrosis.Lab assessments of hyperlipidemia and liver function were also taken before and after weight loss for comparison. At the time of operation, 48 of the patients (70 percent) had metabolic syndrome and hypertension,and 35 (50 percent) had diabetes. The mean initial weight was 339 pounds. At the time of second biopsy, the mean weight had dropped to 236 pounds, an excess body weight loss of 59 percent. Major improvements were noted in the markers of metabolic syndrome, with marked improvement or resolution seen in most comorbid conditions. More than one-third of patients showed resolution of steatosis and inflammation, and 20 percent showed some or complete reversal of fibrosis. No patient experienced progression of abnormal liver morphology or deterioration of hepatic function. Sleeve gastrectomy and laparoscopic banding had less dramatic impacts on weight loss than gastric bypass. This correlated with a beneficial effect on liver morphology. These results highlight the important role that obesity, and by extension the metabolic syndrome,plays in the NAFLD disease process. ![]() |